Item 2.02. Results of Operations and Financial Condition.
Oncternal Therapeutics, Inc. ("Oncternal") estimates that its cash and cash
equivalents were $63.7 million and it had 57.5 million shares of common stock
outstanding as of December 31, 2022. During the quarter ended December 31, 2022,
Oncternal sold 1,947,034 shares of common stock under its at-the-market equity
offering program. These amounts are preliminary and are subject to completion of
financial closing procedures. As a result, these amounts may differ from the
amounts that will be reflected in Oncternal's financial statements as of and for
the quarter ended December 31, 2022.
The information in this Item 2.02 shall not be deemed "filed" for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933,
as amended, except as shall be expressly set forth by specific reference in such
a filing.
Forward-Looking Statements
Oncternal cautions readers that statements contained in this report regarding
matters that are not historical facts are forward-looking statements. These
statements are based on Oncternal's current beliefs and expectations. Such
forward-looking statements include Oncternal's estimated cash and cash
equivalents and capitalization as of December 31, 2022. Such forward-looking
statements involve risks and uncertainties that could cause actual results to
differ materially from predicted or expected results. Such risks and
uncertainties include, but are not limited to, potential changes in estimated
cash and cash equivalents and capitalization based on the completion of
financial closing procedures and release of complete results for the quarter
ended December 31, 2022, risks associated with the clinical development and
process for obtaining regulatory approval of Oncternal's product candidates,
such as potential delays in the commencement, enrollment and completion of
clinical trials, and other risks described in Oncternal's filings with the
Securities and Exchange Commission. Oncternal cautions readers not to place
undue reliance on these forward-looking statements, which speak only as of the
date hereof, and Oncternal undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the date hereof. All
forward-looking statements are qualified in their entirety by this cautionary
statement, which is made under the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995.
1
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses